Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Desiree H. Xu
Observed name:
D. Xu
Institution:
University of California, Davis
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Ambrx (United States),
University of California, Davis
ORCID:
0009-0001-1569-9200
Observed ORCID:
0009-0001-1569-9200
OpenAlex ID:
A5108964794
LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy
2024
·
Shu Ning
, Cameron M. Armstrong
, et al.
·
Cancer Research
·
20
PDF
250TiP HER2-positive and HER2-low breast cancer patients in the ACE-Pan tumor-01 study: Phase I study evaluating ARX788 as monotherapy in advanced solid tumors with HER2 expression or mutation
2022
·
J. Lu
, G.T. Budd
, et al.
·
Annals of Oncology
·
3
Supplementary Information from LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy
2024
·
Shu Ning
, Cameron M. Armstrong
, et al.
Data from LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy
2024
·
Shu Ning
, Cameron M. Armstrong
, et al.
Oligo-Residual Disease in PD-1/PD-L1 Inhibitors Treated Metastatic Non-Small Cell Lung Cancer: Incidence, Pattern of Failure and Clinical Value of Local Consolidative Therapy
2023
·
J. Zhang
, J. Gao
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
PDF
Show more works
View as search
Works count:
5
Citation count:
23
H-index:
2
I10-index:
1
Year
Topic
Type